BIOLASE Names Samuel B. Low, D.D.S., M.S., M.Ed., Vice President, Dental and Clinical Affairs & Chief Dental Officer

Renowned Dental Educator to Lead Dental Affairs, Educational Design and Delivery, and Clinical Research and Support

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that renowned dental educator and periodontist Samuel B. Low, D.D.S., M.S., M.Ed., has been named to the newly created position of Vice President, Dental and Clinical Affairs, and Chief Dental Officer, effective immediately. Dr. Low is based in Florida and will report directly to President and CEO Harold C. Flynn, Jr. He will be responsible for all dental and clinical matters for BIOLASE as well as educational design and delivery.

Dr. Low is Professor Emeritus, University of Florida, College of Dentistry and Associate faculty member of the Pankey Institute, with 30 years of private practice experience in periodontics, lasers and implant placement. He is also a Diplomate of the American Board of Periodontology and past President of the American Academy of Periodontology.

Dr. Low provides dentists and dental hygienists the tools for successfully managing the periodontal patient in general and periodontal practices. He was selected “Dentist of the Year” by the Florida Dental Association, Distinguished Alumnus by the University of Texas Dental School, and the Gordon Christensen Lecturer Recognition Award. He is a Past President of the Florida Dental Association and past ADA Trustee.

As a consultant, Dr. Low has helped enlighten, educate and train clinicians on behalf of BIOLASE, so he is quite familiar with the Company’s products and their clinical use. He has also been a key leader and clinical mentor in the development of new protocols for clinical treatment such as the WATERLASE Periodontitis regimen called “REPAIR” as well as the Peri-implantitis regimen, “REPAIR Implant.”

“I’m thrilled that a clinician of Dr. Low’s caliber has joined BIOLASE to help continue and accelerate our transformation and integrate the practice of dentistry and specifically the management of the periodontal patient into the company. Sam is a world-class educator and brings with him a substantial network in the dental community and its various professional associations coupled with a deep understanding of the challenges that dental professionals face every day. He also understands how integration of dental lasers into a practice can lift anxiety for patients and staff as well as deliver improved patient reported outcomes,” Flynn said. “He will be focused on leading and developing our educational and clinical efforts which are critical areas to master to achieve sustained success as a dental equipment and service provider.”

Dr. Low received his Doctor of Dental Surgery (D.D.S.) and Master of Science (M.S.) degrees from the University of Texas at Houston. He also completed his residency in Periodontics at the University of Texas at Houston, and received a Masters of Education from the University of Florida.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both the dentist and their patients. The Company's proprietary laser products incorporate approximately 255 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 32,000 laser systems to date in over 90 countries around the world. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, our strategic initiatives, the closing of the private placement and expected use of proceeds and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005357/en/

BIOLASE, Inc.
David Dreyer
Chief Financial Officer
888-424-6527
[email protected]
or
DresnerAllenCaron
Rene Caron (Investor Relations)
949-474-4300
[email protected]
or
Len Hall (Media)
949-474-4300
[email protected]

Source: BIOLASE, Inc.

You May Also Be Interested In

• ContextLogic (WISH) Urges Stockholders to Vote FOR the Value Maximizing Transaction with Qoo10 TODAY
• Genetic Technologies (GENE) Announces $2 Million Registered Direct Offering
• SuperCom (SPCB) Prices $2.9M Share Offering at $0.36/sh